FREEHILLS ATTN: ROBERT MCLOUGHLIN Level 48 101 Collins Street MELBOURNE VIC 3000

Certificate of the Registration of a Company

Corporations Act 2001 Paragraph 1274 (2) (b)

This is to certify that

GLOBAL CARDIAC SOLUTIONS PTY LTD

Australian Company Number 102 773 571

is a registered company under the Corporations Act 2001 and is taken to be registered in Queensland.

On the eighth day of November 2002 the company was registered as a proprietary company.

On the sixth day of July 2006 the company converted to a public company and the name changed to HIBERNATION THERAPEUTICS LIMITED

The company is limited by shares.

The day of commencement of registration is the eighth day of November 2002.

Issued by the Australian Securities and Investments Commission on this sixteenth day of November, 2006.

neowc

A delegate of the Australian Securities and Investments Commission



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United Status Patent and Trademark Office Address COMMISSIONER FOR PATENTS Alexandra, Vigina 22313-1430 www.upiu.gov

35

FILING OR 371 (c) DATE ART UNIT FIL FEE REC'D ATTY.DOCKET NO APPL NO. 10/539.222 106/17/2005 FREE 1150 ¥1632 550

DRAWINGS TOT CLMS IND CLMS

CONFIRMATION NO. 4568

SENNIGER POWERS YMK/TBM ONE METROPOLITAN SQUARE 16TH FLOOR **ST LOUIS, MO 63102**

FILING RECEIPT *OC000000017278784*

Date Mailed: 10/25/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Geoffrey Philip Dobson, Queensland, AUSTRALIA;

Assignment For Published Patent Application

- Olobal Cardiac Solutions Pty Ltd. Wulguru, AUSTRALIA-Hibernation Therapeutics Limited

Power of Attorney: The patent practitioners associated with Customer Number 321.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/AU03/01711 12/22/2003

Foreign Applications

UNITED STATES OF AMERICA 60436175 12/23/2002

AUSTRALIA 2003900296 01/23/2003

AUSTRALIA 2003903127 06/20/2003

Projected Publication Date: 01/26/2006

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Organ preconditioning, arrest, protection, preservation and recovery >

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filling of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filling of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.